Lipoic Acid Trisulfide for Muscle Preservation - Quick Reference Sheet
evipedia.ai ← Back

Lipoic Acid Trisulfide for Muscle Preservation

Created on 07/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

An experimental, sulfur-rich form of alpha-lipoic acid. The idea: aging chemically damages the body's muscle-repair signal, and this compound appears to shield it and even make it work better. So far this has been seen only in cells and mice — no human studies exist, and it is not sold or approved. Every muscle benefit remains early and unproven. (Full Review)

Protocol

No established human dose
None established
Investigational compound; not approved or sold
Parent-compound reference range
300–600 mg/day
Alpha-lipoic acid; a reference point only, not validated for the trisulfide
Best time of day
Empty stomach
30–60 minutes before food
Time to effect
Muscle change
Weeks to months
Mechanistic expectation only; unverified, no human data

Benefits

Contraindications
  • Prior insulin autoimmune syndrome, or known HLA-DRB1*04:06 carriers
  • Diabetes on insulin or sulfonylureas without glucose monitoring
  • Thiamine (vitamin B1) deficiency
  • Pregnancy or breastfeeding
  • Active cancer, absent specialist guidance
  • Effectively contraindicated outside a research setting
    •
Key Interactions
  • Antidiabetic medications (insulin, glipizide, glimepiride, metformin)
  • Other glucose-lowering supplements (berberine, chromium, cinnamon extract)
  • Blood-pressure and vasodilating agents (nitrates, sildenafil, amlodipine)
  • Thyroid hormone (levothyroxine)
  • Mineral supplements (iron, calcium, magnesium)
  • Chemotherapy and radiotherapy
    •

Risk & Side Effects

  • Low: Blood-sugar lowering
    •
  • Speculative: Insulin autoimmune syndrome; excess hydrogen sulfide exposure; low blood pressure; gastrointestinal upset, rash, and sulfur odor; unknown human safety of a novel trisulfide
    •

Monitoring

Marker Target Why
Fasting Glucose 70–85 mg/dL Detects the blood-sugar-lowering effect of the lipoic acid backbone
HbA1c 4.8–5.3% Flags hypoglycemia risk and average glucose before and during use
hs-CRP <1.0 mg/L High inflammatory and oxidative load drives the HGF damage this compound targets

Cadence: Baseline, then ~4 weeks, 3 months, and every 6–12 months; more frequent glucose checks in the first month for anyone on glucose-lowering therapy

Qualitative Assessment

  • Handgrip strength
  • Gait speed and chair-stand time
  • Lean body mass by DEXA
  • Energy and exercise recovery
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.